RG7795

From Food & Medicine Encyclopedia


RG7795
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status Investigational
CAS Number 1174920-78-5
PubChem
DrugBank
ChemSpider
KEGG


RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.<ref name=Adis>

RG 7795(link). {{{website}}}. AdisInsight.



</ref> It is an orally-available prodrug of isatoribine,<ref name=Funk>, 

 Tickling the TLR7 to cure viral hepatitis., 
 Journal of Translational Medicine, 
 
 Vol. 12,
 pp. 129,
 DOI: 10.1186/1479-5876-12-129,
 PMID: 24884741,
 PMC: 4039542,</ref> that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.<ref>

, 

 Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration Full text, 
 Genetic Engineering News, 
  
 August 3, 2016,

</ref> Its active metabolite is an [agonist]] of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.<ref name=Funk/>

References[edit]

<references/>

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.

RG7795[edit]

  • RG-7795
    RG-7795
  • Isatoribine
    Isatoribine

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=RG7795&oldid=6336729"